Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2026)
Ginkgo Bioworks Holdings (DNA) posted FCF Margin of 237.95% for Q1 2026, down 66.66% on a QoQ basis from 142.78% in Q4 2025, and down 10620.0% year-over-year from N/an in Q1 2025.
Ginkgo Bioworks Holdings (DNA) FCF Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings' FCF Margin history runs 7 years deep, the most recent figure standing at 237.95% for Q1 2026.
- Quarterly FCF Margin fell 10620.0% year-over-year to 237.95% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 123.62% (up 2441.0% YoY) and the FY2025 annual result came in at 105.04%, up 6327.0% from the prior year.
- FCF Margin was 237.95% for Q1 2026 at Ginkgo Bioworks Holdings, down from 142.78% in the prior quarter.
- Across five years, FCF Margin topped out at 10.5% in Q1 2022 and bottomed at 252.92% in Q1 2024.
- A 5-year average of 123.16% and a median of 115.52% in 2024 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2022 — FCF Margin jumped 14839 bps — and 2024, when it plunged 19952 bps.
- Ginkgo Bioworks Holdings' FCF Margin stood at 149.36% in 2022, then surged by 74 bps to 39.45% in 2023, then sank by 506 bps to 238.97% in 2024, then surged by 40 bps to 142.78% in 2025, then slumped by 67 bps to 237.95% in 2026.
- Business Quant data shows DNA's FCF Margin at 237.95% in Q1 2026, 142.78% in Q4 2025, and 100.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Ginkgo Bioworks Holdings | 517.16 Mn | 373.30 Mn | 16.38 Mn | -237.95% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -237.95% |
| Dec 31, 2025 | -142.78% |
| Sep 30, 2025 | -100.78% |
| Jun 30, 2025 | -83.72% |
| Mar 31, 2025 | -131.76% |
| Dec 31, 2024 | -238.97% |
| Sep 30, 2024 | -115.52% |
| Jun 30, 2024 | -139.69% |
| Mar 31, 2024 | -252.92% |
| Dec 31, 2023 | -39.45% |
| Sep 30, 2023 | -78.13% |
| Jun 30, 2023 | -108.07% |
| Mar 31, 2023 | -136.34% |
| Dec 31, 2022 | -149.36% |
| Sep 30, 2022 | -57.14% |
| Jun 30, 2022 | -70.56% |
| Mar 31, 2022 | -10.50% |
| Dec 31, 2021 | -77.22% |
| Sep 30, 2021 | -13.75% |
| Jun 30, 2021 | -135.08% |